[go: up one dir, main page]

TR200201296T2 - Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri - Google Patents

Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri

Info

Publication number
TR200201296T2
TR200201296T2 TR2002/01296T TR200201296T TR200201296T2 TR 200201296 T2 TR200201296 T2 TR 200201296T2 TR 2002/01296 T TR2002/01296 T TR 2002/01296T TR 200201296 T TR200201296 T TR 200201296T TR 200201296 T2 TR200201296 T2 TR 200201296T2
Authority
TR
Turkey
Prior art keywords
heteroaryl
compounds
formula
anticancer agents
derivatives useful
Prior art date
Application number
TR2002/01296T
Other languages
English (en)
Inventor
Vera Yang Bingwei
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200201296T2 publication Critical patent/TR200201296T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Mevcut bulus, R ,R ,R ,R4,R5,R6,R7,R8,R9 ve Z'nin burada tanimlandigi gibi oldugu formül (I)'e ait bilesiklerle ve bunun farmasötik açidan kabul gören tuzlari ve solvatlariyla ilgilidir. Bulus, formül (I)'e ait bilesikleri ihtiva eden farmasötik kompozisyonlarla ve formül (I)'e ait bilesiklerin memeliye uygulanmasi suretiyle bir memelide kanser dahil anormal hücre büyümesinin önlenmesine yönelik metotlarla da ilgilidir. Bulus, formül (I)'e ait bilesiklerin sentezlenmesinde faydali ara baglar ve metotlarla da ilgilidir.
TR2002/01296T 1999-02-11 2000-02-04 Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri TR200201296T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11970299P 1999-02-11 1999-02-11

Publications (1)

Publication Number Publication Date
TR200201296T2 true TR200201296T2 (tr) 2002-07-22

Family

ID=22385869

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/01296T TR200201296T2 (tr) 1999-02-11 2000-02-04 Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
TR2002/01297T TR200201297T2 (tr) 1999-02-11 2000-02-04 Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2002/01297T TR200201297T2 (tr) 1999-02-11 2000-02-04 Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.

Country Status (39)

Country Link
US (3) US6258824B1 (tr)
EP (1) EP1150973B1 (tr)
JP (3) JP4090200B2 (tr)
KR (1) KR20010102073A (tr)
CN (1) CN1340051A (tr)
AP (1) AP2001002241A0 (tr)
AR (1) AR028985A1 (tr)
AT (1) ATE297916T1 (tr)
AU (1) AU2124800A (tr)
BG (1) BG105860A (tr)
BR (1) BR0008202A (tr)
CA (1) CA2362394C (tr)
CO (1) CO5140097A1 (tr)
CZ (1) CZ20012910A3 (tr)
DE (1) DE60020812T2 (tr)
DZ (1) DZ3009A1 (tr)
EA (1) EA200100766A1 (tr)
EE (1) EE200100425A (tr)
ES (1) ES2243228T3 (tr)
GT (1) GT200000014A (tr)
HK (1) HK1042096A1 (tr)
HN (1) HN2000000019A (tr)
HR (1) HRP20010574A2 (tr)
HU (1) HUP0105231A3 (tr)
ID (1) ID29584A (tr)
IL (1) IL144307A0 (tr)
IS (1) IS5997A (tr)
MA (1) MA26718A1 (tr)
NO (1) NO20013909L (tr)
OA (1) OA11833A (tr)
PA (1) PA8490601A1 (tr)
PE (1) PE20001464A1 (tr)
PL (1) PL349839A1 (tr)
SK (1) SK11002001A3 (tr)
SV (1) SV2001000020A (tr)
TN (1) TNSN00028A1 (tr)
TR (2) TR200201296T2 (tr)
WO (1) WO2000047574A1 (tr)
ZA (1) ZA200106520B (tr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4530537B2 (ja) * 1998-07-06 2010-08-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ インビボ放射線増感特性をもつファルネシルタンパク質トランスフェラーゼ阻害剤
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
CA2390164C (en) * 1999-11-05 2011-03-29 Cytovia, Inc. Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7053117B2 (en) * 2001-05-16 2006-05-30 Cytovia, Inc. Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
ATE259365T1 (de) * 1999-11-30 2004-02-15 Pfizer Prod Inc Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1253921A4 (en) * 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
AU2001293829A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-((substituted phenyl)methyl)-quinoline and quinazoline derivatives
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
EP1332133B1 (en) * 2000-10-02 2008-07-09 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
DE60139080D1 (de) 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
DE60117847T2 (de) 2000-12-27 2006-11-16 Janssen Pharmaceutica N.V. Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20030139332A1 (en) * 2001-07-09 2003-07-24 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de) * 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
AU2003226737B2 (en) * 2002-03-29 2008-09-04 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
EP1497295B1 (en) 2002-04-15 2006-08-16 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7476741B2 (en) 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003097806A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
SI1585743T1 (sl) * 2002-12-19 2007-08-31 Pfizer Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
CN103265477B (zh) 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
WO2004076446A1 (ja) * 2003-02-27 2004-09-10 Chugai Seiyaku Kabushiki Kaisha ベンゾチオフェン誘導体
WO2005009967A2 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
SI1784396T1 (sl) * 2004-08-26 2011-03-31 Pfizer S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
JP2008510792A (ja) * 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
AU2005294430A1 (en) * 2004-10-07 2006-04-20 Cytovia, Inc. Substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis
JP2009508809A (ja) 2005-07-29 2009-03-05 チルドレンズ ホスピタル メディカル センター ＲＡＣ−１ＧＴＰａｓｅのＧＴＰａｓｅ阻害因子とその使用方法およびその結晶構造
CN101517068B (zh) 2005-09-07 2017-02-08 安进弗里蒙特公司 活化素受体样激酶‑1的人单克隆抗体
JP5055284B2 (ja) 2005-09-20 2012-10-24 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
JP2009521470A (ja) * 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
MX2009001715A (es) 2006-08-21 2009-02-25 Hoffmann La Roche Terapia tumoral con un anticuerpo anti-vegf.
DK2155733T3 (da) * 2007-05-23 2012-10-29 Allergan Inc Cykliske lactamer til behandling af glaukom eller forhøjet intraokulært tryk
RU2472788C9 (ru) * 2007-05-23 2013-04-20 Аллерган, Инк. (бициклогетероарил)имидазолил)метилгетероарильные соединения как агонисты адренергических рецепторов
US8129356B2 (en) * 2007-10-01 2012-03-06 Vanderbilt University Bmx mediated signal transduction in irradiated vascular endothelium
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
ES2738493T3 (es) 2013-03-14 2020-01-23 Tolero Pharmaceuticals Inc Inhibidores de JAK2 y ALK2 y métodos para su uso
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
CN108003150A (zh) * 2016-10-31 2018-05-08 河南工业大学 4-杂芳基喹啉酮衍生物的制备方法及其应用
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
US4835154A (en) * 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US5136085A (en) * 1990-11-28 1992-08-04 Glaxo Inc. Synthesis of 2-aminobenzophenones
US5053543A (en) * 1990-11-28 1991-10-01 Glaxo Inc. Synthesis of 2-aminobenzophenones
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU711142B2 (en) * 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
ES2182327T3 (es) * 1997-06-02 2003-03-01 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinlinona como inhibidores de la proliferacion de celulas de musculos lisos.
IL141239A0 (en) 1998-08-27 2002-03-10 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri

Also Published As

Publication number Publication date
ZA200106520B (en) 2002-08-26
PE20001464A1 (es) 2000-12-20
NO20013909D0 (no) 2001-08-10
US6258824B1 (en) 2001-07-10
SV2001000020A (es) 2001-11-08
JP2004182741A (ja) 2004-07-02
CZ20012910A3 (cs) 2002-02-13
CA2362394C (en) 2006-01-17
SK11002001A3 (sk) 2002-05-09
EE200100425A (et) 2002-12-16
EA200100766A1 (ru) 2002-02-28
US20020120145A1 (en) 2002-08-29
HN2000000019A (es) 2001-07-30
CN1340051A (zh) 2002-03-13
AU2124800A (en) 2000-08-29
NO20013909L (no) 2001-10-08
EP1150973B1 (en) 2005-06-15
MA26718A1 (fr) 2004-12-20
BR0008202A (pt) 2002-02-19
JP4216740B2 (ja) 2009-01-28
US6710209B2 (en) 2004-03-23
GT200000014A (es) 2001-08-03
JP2002536444A (ja) 2002-10-29
EP1150973A1 (en) 2001-11-07
TR200201297T2 (tr) 2002-06-21
AR028985A1 (es) 2003-06-04
JP2005002124A (ja) 2005-01-06
OA11833A (en) 2005-08-23
BG105860A (en) 2002-03-29
JP4090200B2 (ja) 2008-05-28
HRP20010574A2 (en) 2002-12-31
US20020019530A1 (en) 2002-02-14
ID29584A (id) 2001-09-06
WO2000047574A1 (en) 2000-08-17
ATE297916T1 (de) 2005-07-15
PA8490601A1 (es) 2002-07-30
ES2243228T3 (es) 2005-12-01
AP2001002241A0 (en) 2001-09-30
PL349839A1 (en) 2002-09-23
IL144307A0 (en) 2002-05-23
CA2362394A1 (en) 2000-08-17
TNSN00028A1 (fr) 2005-11-10
HUP0105231A2 (hu) 2002-04-29
HUP0105231A3 (en) 2003-01-28
DE60020812D1 (de) 2005-07-21
KR20010102073A (ko) 2001-11-15
HK1042096A1 (zh) 2002-08-02
DE60020812T2 (de) 2006-05-04
CO5140097A1 (es) 2002-03-22
DZ3009A1 (fr) 2004-03-27
US6388092B2 (en) 2002-05-14
IS5997A (is) 2001-07-10

Similar Documents

Publication Publication Date Title
TR200201296T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
BR9805734A (pt) Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos.
TR200102136T2 (tr) Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler.
BG105365A (en) Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
BR9913315A (pt) Derivados de quinolin-2-ona úteis como agentes anticâncer
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
DE69709493D1 (de) Substituierte Indazolderivate
TR200102315T2 (tr) Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri.
ECSP003347A (es) Derivados quinolin - 2- ona sustituidos con heteroarilo utiles como agentes anticancerigenos
ECSP993117A (es) Derivados de quinolin -2 - ona utiles como agentes contra el cancer